Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug
Portfolio Pulse from
Applied Therapeutics' stock dropped significantly after the FDA rejected its application for a drug intended to treat Galactosemia, a rare metabolic disease.
November 29, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Applied Therapeutics' stock experienced a sharp decline following the FDA's rejection of its drug application for treating Galactosemia.
The FDA's rejection of the drug application is a significant setback for Applied Therapeutics, directly impacting its stock price negatively. The rejection implies potential delays in revenue generation from this drug, affecting investor sentiment.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100